CAJ | 학술논문

目的：观察雷替曲塞联合伊立替康方案治疗晚期结直肠癌的近期疗效和安全性。方法：经病理组织学或细胞学确诊的44例晚期结直肠癌患者随机分为对照组（22例）和实验组（22例）。对照组，伊立替康180mg/m2静滴90min d1，亚叶酸钙400mg/m2静滴d1，5-氟尿嘧啶400mg/m2静推d1，2000mg/m2静滴46h d1。实验组，伊立替康180mg/m2静滴90min d1，雷替曲塞3mg/m2静滴15min d1，21天为1周期，2周期后评价疗效。结果：对照组PR 3例、SD 5例、PD 14例，实验组PR 4例、SD 6例、PD 12例，两组均无CR病例。两组有效率（RR）分别为13.6%和18.2%，疾病控制率（DCR）分别为36.4%和45.5%（p﹥0.05）。对照组乏力、周围神经毒性、黏膜炎和脉管炎发生率分别为72.7%、31.8%、36.4%和27.3%（p﹤0.05），实验组血红蛋白减少发生率为59.1%（p﹤0.05）。结论：雷替曲塞联合伊立替康方案与FOLFIRI方案的近期疗效相当，但不良反应更轻，可以作为晚期结直肠癌的有效姑息治疗方案。
목적：관찰뢰체곡새연합이립체강방안치료만기결직장암적근기료효화안전성。방법：경병리조직학혹세포학학진적44례만기결직장암환자수궤분위대조조（22례）화실험조（22례）。대조조，이립체강180mg/m2정적90min d1，아협산개400mg/m2정적d1，5-불뇨밀정400mg/m2정추d1，2000mg/m2정적46h d1。실험조，이립체강180mg/m2정적90min d1，뢰체곡새3mg/m2정적15min d1，21천위1주기，2주기후평개료효。결과：대조조PR 3례、SD 5례、PD 14례，실험조PR 4례、SD 6례、PD 12례，량조균무CR병례。량조유효솔（RR）분별위13.6%화18.2%，질병공제솔（DCR）분별위36.4%화45.5%（p﹥0.05）。대조조핍력、주위신경독성、점막염화맥관염발생솔분별위72.7%、31.8%、36.4%화27.3%（p﹤0.05），실험조혈홍단백감소발생솔위59.1%（p﹤0.05）。결론：뢰체곡새연합이립체강방안여FOLFIRI방안적근기료효상당，단불량반응경경，가이작위만기결직장암적유효고식치료방안。
Objective:To compare the efficacy and safety between raltitrexed and irinotecan with FOLFIRI for pa-tients with advanced colorectal cancer. Methods:A total of 44 patients with advanced colorectal cancer were divided randomly into two groups. There were 22 patients for FOLFIRI regimen group( control group:irinotecan 180mg/m2 iv d1 ,leucovorin 400mg/m2 iv d1 ,fluorouracil 400mg/m2 iv d1 ,fluorouracil 2000mg/m2 iv 46h d1 )and 22 patients for raltitrexed plus irinotecan regimen group(treatment group:irinotecan 180mg/m2 iv d1,raltitrexed 3mg/m2 iv d1). Both two regimens were 21 days as a cycle,and a total of 2 cycles was applied. The efficacy and side effects were evaluated after 2 cycles. Results:Patients in control group received 3 PR,5 SD,14 PD to contrast treatment group 4 PR,6 SD, 12 PD,no CR case. No statistical difference was found between the two groups in regard to response rate(13. 6% vs. 18. 2%)and disease control rate(36. 4% vs. 45. 5%). FOLFIRI regimen had higher frequency hypodynamia,periph-eral nerve venenosity,mucositis and angiitis(p﹤0. 05),while raltitrexed plus irinotecan regimen had higher frequen-cy of hemophthisis(p﹤0. 05). Conclusion:Raltitrexed plus irinotican regimen is effective for metastatic colorectal cancer.